Disclaimer: All content on BestGLP1Provider.com is for informational purposes only and does not constitute medical advice
Real evidence: A 12-week study: submaximal semaglutide improved metabolic markers but showed no change in the inflammatory markers IL-6, TNF-, or PAI-1 Semaglutide dose-response studies: effects require 0.2 mg/day, and even those effects are diminished when adjusted for weight change Meta-analyses showing anti-inflammatory effects correlate with improvements in insulin resistance and weight loss, not with microdosing voodoo magic
VasQ TM has a Breakthrough Device designation and marketing authorization from FDA for the indication covered by the Breakthrough Device designation (as explained in more detail of the newness criterion) and therefore was not evaluated for substantial clinical improvement
And that's a big part of how the PBMs make a lot of their money, the GPO stuff we talked about, but also forcing an employer to go through the specialty mail order company that charges an arm and the leg
"I always tell my patients that if they have a bag of Doritos, they will eat it
Knockdown of one factor in the pathway may improve but not fully disrupt the muco-inflammatory cycle due to the multifactorial and overlapping regulators of mucin secretion
